Publicaciones científicas
COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study
Joaquín Martínez-López 1 , Javier De la Cruz 2 , Rodrigo Gil-Manso 1 , Adrián Alegre 3 , Javier Ortiz 3 , Pilar Llamas 4 , Yolanda Martínez 4 , José-Ángel Hernández-Rivas 5 , Isabel González-Gascón 5 , Celina Benavente 6 , Pablo Estival Monteliu 6 , Víctor Jiménez-Yuste 7 , Miguel Canales 8 , Mariana Bastos 9 10 , Mi Kwon 9 10 , Susana Valenciano 11 , Marta Callejas-Charavia 12 , Javier López-Jiménez 13 , Pilar Herrera 13 , Rafael Duarte 14 , Lucía Núñez Martín-Buitrago 14 , Pedro Sanchez Godoy 15 , Cristina Jacome Yerovi 15 , Pilar Martínez-Barranco 16 , María García Roa 16 , Cristian Escolano Escobar 17 , Arturo Matilla 18 , Belén Rosado Sierra 19 , María Concepción Aláez-Usón 20 , Keina Quiroz-Cervantes 21 , Carmen Martínez-Chamorro 22 , Jaime Pérez-Oteyza 11 , Rafael Martos-Martinez 23 , Regina Herráez 24 , Clara González-Santillana 25 , Juan Francisco Del Campo 26 , Arancha Alonso 27 , Adolfo de la Fuente 28 , Adriana Pascual 29 , Rosalía Bustelos-Rodriguez 30 , Ana Sebrango 31 , Elena Ruiz 32 , Eriel Alexis Marcheco-Pupo 33 , Carlos Grande 8 , Ángel Cedillo 34 , Carlos Lumbreras 35 , Andrés Arroyo Barea 1 , José Manuel Casas-Rojo 36 , Maria Calbacho 1 , José Luis Diez-Martín 9 10 , Julio García-Suárez 12 ; Asociación Madrileña de Hematología y Hemoterapia (AMHH)
Abstract
Mortality rates for COVID-19 have declined over time in the general population, but data in patients with hematologic malignancies are contradictory.
We identified independent prognostic factors for COVID-19 severity and survival in unvaccinated patients with hematologic malignancies, compared mortality rates over time and versus non-cancer inpatients, and investigated post COVID-19 condition. Data were analyzed from 1166 consecutive, eligible patients with hematologic malignancies from the population-based HEMATO-MADRID registry, Spain, with COVID-19 prior to vaccination roll-out, stratified into early (February-June 2020; n = 769 (66%)) and later (July 2020-February 2021; n = 397 (34%)) cohorts.
Propensity-score matched non-cancer patients were identified from the SEMI-COVID registry. A lower proportion of patients were hospitalized in the later waves (54.2%) compared to the earlier (88.6%), OR 0.15, 95%CI 0.11-0.20.
The proportion of hospitalized patients admitted to the ICU was higher in the later cohort (103/215, 47.9%) compared with the early cohort (170/681, 25.0%, 2.77; 2.01-3.82). The reduced 30-day mortality between early and later cohorts of non-cancer inpatients (29.6% vs. 12.6%, OR 0.34; 0.22-0.53) was not paralleled in inpatients with hematologic malignancies (32.3% vs. 34.8%, OR 1.12; 0.81-1.5). Among evaluable patients, 27.3% had post COVID-19 condition.
These findings will help inform evidence-based preventive and therapeutic strategies for patients with hematologic malignancies and COVID-19 diagnosis.
CITA DEL ARTÍCULO Cancers (Basel). 2023 Feb 27;15(5):1497. doi: 10.3390/cancers15051497
Nuestros autores
